Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


 0.34 (0.50%)

Market Cap$9,626,234,468

05/25/17  9:49 a.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference 05/09/17

Read more

Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132) 05/05/17

Read more


Bank of America Merrill Lynch 2017 Healthcare Conference05/16/17 9:20 a.m. PTView event1st Quarter 2017 Financial Results04/27/17 4:30 p.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources